Efficacy and safety of dupilumab in patients with prurigo nodularis.
作者信息
Li Xu, Li Jiaojiao, Li Dan, Guo Jingxue, Yang Xueying, Fan Change, Cai Huijiao, An Caiyan, Li Yanfei, Zhang Junjing
机构信息
Department of Allergy, The First Hospital of Hohhot, Hohhot, 010030, China.
Department of Dermatology, The First Hospital of Hohhot, Hohhot, 010030, China.
出版信息
Arch Dermatol Res. 2024 Oct 14;316(10):676. doi: 10.1007/s00403-024-03387-1.
PMID:39400706
Abstract
摘要
相似文献
1
Efficacy and safety of dupilumab in patients with prurigo nodularis.
Arch Dermatol Res. 2024 Oct 14;316(10):676. doi: 10.1007/s00403-024-03387-1.
2
A critical review of dupilumab for adult patients with prurigo nodularis.
Expert Rev Clin Immunol. 2024 Mar;20(3):249-254. doi: 10.1080/1744666X.2023.2268291. Epub 2023 Oct 12.
3
Dupilumab for prurigo nodularis: Case series and review of the literature.
Dermatol Ther. 2020 Mar;33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16.
4
Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e74-e76. doi: 10.1111/jdv.15957. Epub 2019 Oct 17.
5
Dupilumab for the treatment of prurigo nodularis: A systematic review.
Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. eCollection 2023.
6
Safety and Effectiveness of Dupilumab in Prurigo Nodularis.
J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):162-163. doi: 10.18176/jiaci.0550. Epub 2020 Jun 23.
7
Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis: A single-center, real-world prospective study.
J Am Acad Dermatol. 2024 May;90(5):1076-1078. doi: 10.1016/j.jaad.2024.01.036. Epub 2024 Jan 29.
8
Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review.
Acta Derm Venereol. 2019 Sep 1;99(10):905-906. doi: 10.2340/00015555-3243.
9
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study.
J Eur Acad Dermatol Venereol. 2024 Oct;38(10):e892-e895. doi: 10.1111/jdv.19980. Epub 2024 Mar 27.
10
Dupilumab for pediatric prurigo nodularis: A case report.
Pediatr Dermatol. 2021 Jan;38(1):334-335. doi: 10.1111/pde.14464. Epub 2020 Nov 28.
本文引用的文献
1
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Nat Med. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4.
2
Prurigo nodularis: Pathogenesis and management.
J Am Acad Dermatol. 2020 Dec;83(6):1567-1575. doi: 10.1016/j.jaad.2020.04.182. Epub 2020 May 24.
3
Prurigo nodularis: Epidemiology and clinical features.
J Am Acad Dermatol. 2020 Dec;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183. Epub 2020 May 23.
Zotero 插件